In recent years, more prescriptions for GLP-1 drugs were written to treat obesity than Type 2 diabetes, adding to accessibility and shortage concerns, according to a study published July 23 in Annals of Internal Medicine.
GLP-1s
Whether a GLP-1 medication is approved for diabetes or chronic weight management, declaring one therapy as "best" for weight loss is tricky.
A new study from researchers at Oxford University in England has found that semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, may be tied to a lower risk of cognitive issues, including dementia.
Counterfeit Ozempic presentations, known as "faux-zempic," are on the rise in legal and illegal supply chains, The New York Times reported July 12.
Citing high costs, payers are favoring bariatric surgeries over Wegovy and similar medications, according to an NYU Langone expert. It's unclear if insurers' policies can quell the booming popularity of GLP-1 weight loss drugs, though.
Advertisement
Pfizer's oral GLP-1 drug candidate, danuglipron, has shown promising results that support daily dosing, the company said July 11.
A week after a study connected Ozempic and Wegovy to an eye condition that can cause partial blindness, two ophthalmology organizations said they have "been aware of other vision changes for some time."
Using Mounjaro for one year led to more weight loss than Ozempic did in a study of 18,386 patients, according to the results published July 8 in JAMA Internal Medicine.
GLP-1 drugs such as Ozempic and Wegovy may lower the risk of developing certain obesity-related cancers, according to a new study from researchers at Case Western Reserve University in Cleveland.
A new study suggests patients taking semaglutide — the active ingredient in Ozempic and Wegovy — may be at higher risk of an eye condition that can cause blindness. However, study authors and experts told NBC News the findings only…